Protective Effect of Bisphosphonates on Endometrial Cancer Incidence in Data From the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial

被引:11
作者
Hensley, Sharon [1 ]
Rattan, Ramandeep [2 ]
Buekers, Thomas E. [2 ]
Munkarah, Adnan R. [2 ]
机构
[1] Henry Ford Hlth Syst, Dept Publ Hlth Sci, Detroit, MI 48202 USA
[2] Henry Ford Hlth Syst, Dept Womens Hlth, Detroit, MI 48202 USA
基金
美国国家卫生研究院;
关键词
epidemiology; endometrial cancer; bisphosphonates; cancer incidence; chemoprevention; MEVALONATE PATHWAY; MATRIX METALLOPROTEINASES; EXCESS MORTALITY; HIP FRACTURE; BREAST; INVASION; INHIBIT; LOCALIZATION; EXPRESSION; MIGRATION;
D O I
10.1002/cncr.28952
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
BACKGROUND: Preclinical studies have demonstrated antitumor effects of bisphosphonates. The objective of the current study was to determine the effect of exposure to bisphosphonate on the incidence of endometrial cancer. METHODS: The authors used data from the National Cancer Institute's Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial, which collected data on all cancers. In year 5, all participants were asked to complete a self-administered supplemental questionnaire (SQX) that included questions regarding bone medication use. For women without a cancer diagnosis at the time of the SQX, the authors identified whether a woman reported current or former use of a nitrogenous bisphosphonate (NBP), defined as ever-use, and compared them with women never exposed to an NBP. Women with missing information were excluded as were women who reported undergoing a hysterectomy. Incidence rates and rate ratios were calculated with 95% confidence intervals (95% CIs). Cox proportional hazard ratios were also calculated and adjusted for covariates. RESULTS: A total of 29,254 women were included in the current analysis; an additional 77 cases of endometrial cancer have been diagnosed since the SQX. The incidence rate for endometrial cancer among women exposed to NBPs was 8.7 per 10,000 person-years versus 17.7 per 10,000 person-years among never-exposed women (rate ratio, 0.49; 95% CI, 0.30-0.80). The effect was similar after adjusting for all the covariates in the Cox proportional hazards analysis, with a hazard ratio of 0.56 (95% CI, 0.34-0.93). CONCLUSIONS: The results of the current study suggest that use of NBPs may have a protective effect on the incidence of endometrial cancer. However, additional studies are needed that include other potential confounders and a larger sample. (C) 2014 American Cancer Society.
引用
收藏
页码:441 / 447
页数:7
相关论文
共 31 条
[1]   Reduction of mouse mammary tumor formation and metastasis by lovastatin, an inhibitor of the mevalonate pathway of cholesterol synthesis [J].
Alonso, DF ;
Farina, HG ;
Skilton, G ;
Gabri, MR ;
De Lorenzo, MS ;
Gomez, DE .
BREAST CANCER RESEARCH AND TREATMENT, 1998, 50 (01) :83-93
[2]  
[Anonymous], 2004, Bone Health and Osteoporosis: A Report of the Surgeon General
[3]  
[Anonymous], 2013, CANC FACTS FIG 2013
[4]   Clinical outcomes and mortality after hip fracture: A 2-year follow-up study [J].
Baudoin, C ;
Fardellone, P ;
Bean, K ;
OstertagEzembe, A ;
Hervy, F .
BONE, 1996, 18 (03) :S149-S157
[5]  
Boissier S, 2000, CANCER RES, V60, P2949
[6]   Anti-Tumour Effects of Bisphosphonates - What have we Learned from In Vivo Models? [J].
Brown, H. K. ;
Holen, I. .
CURRENT CANCER DRUG TARGETS, 2009, 9 (07) :807-823
[7]   R115777 (Zarnestra®)/Zoledronic acid (Zometa®) cooperation on inhibition of prostate cancer proliferation is paralleled by Erk/Akt inactivation and reduced Bcl-2 and bad phosphorylation [J].
Caraglia, Michele ;
Marra, Monica ;
Leonetti, Carlo ;
Meo, Giuseppina ;
D'Alessandro, Anna Maria ;
Baldi, Alfonso ;
Santini, Danele ;
Tonini, Giuseppe ;
Bertieri, Raffaello ;
Zupi, Gabriella ;
Budillon, Alfredo ;
Abbruzzese, Alberto .
JOURNAL OF CELLULAR PHYSIOLOGY, 2007, 211 (02) :533-543
[8]   Oral Bisphosphonate Use and Breast Cancer Incidence in Postmenopausal Women [J].
Chlebowski, Rowan T. ;
Chen, Zhao ;
Cauley, Jane A. ;
Anderson, Garnet ;
Rodabough, Rebecca J. ;
McTiernan, Anne ;
Lane, Dorothy S. ;
Manson, JoAnn E. ;
Snetselaar, Linda ;
Yasmeen, Shagufta ;
O'Sullivan, Mary Jo ;
Safford, Monika ;
Hendrix, Susan L. ;
Wallace, Robert B. .
JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (22) :3582-3590
[9]   Bisphosphonates and cancer-induced bone disease:: Beyond their antiresorptive activity [J].
Clézardin, P ;
Ebetino, FH ;
Fournier, PGJ .
CANCER RESEARCH, 2005, 65 (12) :4971-4974
[10]   In vitro and in vivo antitumor effects of bisphosphonates [J].
Clézardin, P ;
Fournier, P ;
Boissier, S ;
Peyruchaud, O .
CURRENT MEDICINAL CHEMISTRY, 2003, 10 (02) :173-180